CN116751705A - Lactobacillus reuteri with effect of improving colpitis and application thereof - Google Patents
Lactobacillus reuteri with effect of improving colpitis and application thereof Download PDFInfo
- Publication number
- CN116751705A CN116751705A CN202310556089.9A CN202310556089A CN116751705A CN 116751705 A CN116751705 A CN 116751705A CN 202310556089 A CN202310556089 A CN 202310556089A CN 116751705 A CN116751705 A CN 116751705A
- Authority
- CN
- China
- Prior art keywords
- lactobacillus reuteri
- vaginitis
- reuteri
- colpitis
- medicament
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 241000186604 Lactobacillus reuteri Species 0.000 title claims abstract description 56
- 229940001882 lactobacillus reuteri Drugs 0.000 title claims abstract description 56
- 206010046914 Vaginal infection Diseases 0.000 title claims abstract description 39
- 230000000694 effects Effects 0.000 title description 5
- 201000008100 Vaginitis Diseases 0.000 claims abstract description 23
- 239000003814 drug Substances 0.000 claims abstract description 20
- 241000207201 Gardnerella vaginalis Species 0.000 claims abstract description 18
- 230000000813 microbial effect Effects 0.000 claims abstract description 18
- 241000222122 Candida albicans Species 0.000 claims abstract description 17
- 229940095731 candida albicans Drugs 0.000 claims abstract description 17
- 241000191967 Staphylococcus aureus Species 0.000 claims abstract description 16
- 244000005700 microbiome Species 0.000 claims abstract description 5
- 235000013305 food Nutrition 0.000 claims abstract description 4
- 241001465754 Metazoa Species 0.000 claims description 12
- 238000002360 preparation method Methods 0.000 claims description 11
- 239000002552 dosage form Substances 0.000 claims description 10
- 239000000499 gel Substances 0.000 claims description 6
- 239000006210 lotion Substances 0.000 claims description 6
- 238000004519 manufacturing process Methods 0.000 claims description 6
- 239000002674 ointment Substances 0.000 claims description 6
- 239000000463 material Substances 0.000 claims description 3
- 230000002265 prevention Effects 0.000 claims 1
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 abstract description 22
- 229940079593 drug Drugs 0.000 abstract description 7
- 208000015181 infectious disease Diseases 0.000 abstract description 7
- 230000000844 anti-bacterial effect Effects 0.000 abstract description 5
- 238000004321 preservation Methods 0.000 abstract description 4
- 230000009933 reproductive health Effects 0.000 abstract description 4
- 230000032683 aging Effects 0.000 abstract description 2
- 230000004888 barrier function Effects 0.000 abstract description 2
- 210000005000 reproductive tract Anatomy 0.000 abstract description 2
- 239000000243 solution Substances 0.000 description 14
- 241000894006 Bacteria Species 0.000 description 6
- 238000012258 culturing Methods 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 239000001963 growth medium Substances 0.000 description 6
- 230000001580 bacterial effect Effects 0.000 description 5
- 208000004926 Bacterial Vaginosis Diseases 0.000 description 4
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 210000001215 vagina Anatomy 0.000 description 4
- 108020004465 16S ribosomal RNA Proteins 0.000 description 3
- IHPYMWDTONKSCO-UHFFFAOYSA-N 2,2'-piperazine-1,4-diylbisethanesulfonic acid Chemical compound OS(=O)(=O)CCN1CCN(CCS(O)(=O)=O)CC1 IHPYMWDTONKSCO-UHFFFAOYSA-N 0.000 description 3
- 230000003213 activating effect Effects 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 230000000877 morphologic effect Effects 0.000 description 3
- 238000012163 sequencing technique Methods 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 102000016938 Catalase Human genes 0.000 description 2
- 108010053835 Catalase Proteins 0.000 description 2
- 238000003794 Gram staining Methods 0.000 description 2
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 244000052616 bacterial pathogen Species 0.000 description 2
- 235000014655 lactic acid Nutrition 0.000 description 2
- 239000004310 lactic acid Substances 0.000 description 2
- 238000009630 liquid culture Methods 0.000 description 2
- 239000011259 mixed solution Substances 0.000 description 2
- 206010003693 Atrophic vulvovaginitis Diseases 0.000 description 1
- 208000003322 Coinfection Diseases 0.000 description 1
- 241000186216 Corynebacterium Species 0.000 description 1
- 241000207202 Gardnerella Species 0.000 description 1
- 241000606790 Haemophilus Species 0.000 description 1
- 241000186660 Lactobacillus Species 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 208000008350 Pruritus Vulvae Diseases 0.000 description 1
- 208000007074 Trichomonas Vaginitis Diseases 0.000 description 1
- 208000025206 Trichomonas vaginitis urogenital infection Diseases 0.000 description 1
- 208000037009 Vaginitis bacterial Diseases 0.000 description 1
- 206010056530 Vulvovaginal pruritus Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 210000003756 cervix mucus Anatomy 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 230000007803 itching Effects 0.000 description 1
- 230000000366 juvenile effect Effects 0.000 description 1
- 229940039696 lactobacillus Drugs 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 201000010808 postmenopausal atrophic vaginitis Diseases 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 239000006152 selective media Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 241001148471 unidentified anaerobic bacterium Species 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
- C12N1/205—Bacterial isolates
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
- C12R2001/225—Lactobacillus
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Genetics & Genomics (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Mycology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Oncology (AREA)
- General Engineering & Computer Science (AREA)
- Communicable Diseases (AREA)
- Tropical Medicine & Parasitology (AREA)
- Virology (AREA)
- Gynecology & Obstetrics (AREA)
- Biochemistry (AREA)
- Reproductive Health (AREA)
- Endocrinology (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Nutrition Science (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
The application discloses lactobacillus reuteri with a function of improving colpitis and application thereof, and the lactobacillus reuteri is specifically lactobacillus reuteri (Limosilactobacillus reuteri) HR7, which is preserved in the Guangdong province microorganism strain preservation center, and the preservation number is GDMCC No:63350; the lactobacillus reuteri has certain antibacterial effect on gardnerella vaginalis, staphylococcus aureus and candida albicans, and can produce hydrogen peroxide at high yield, so that the lactobacillus reuteri can improve colpitis caused by microbial infection; therefore, the lactobacillus reuteri can be used for preparing vaginal care products and medicines or foods for preventing and treating vaginitis, can establish a vaginal microecological barrier and delay genital tract aging, and provides powerful guarantee for female reproductive health.
Description
Technical Field
The application relates to the technical field of microorganisms, in particular to lactobacillus reuteri with a function of improving colpitis and application thereof.
Background
Vaginitis (Vaginitis), a group of conditions that lead to vulvovaginal symptoms such as itching, burning, irritation and abnormal fluid flow. The vagina of a normal healthy woman has natural defensive function against pathogen invasion due to the characteristics of anatomical tissues. Clinically, there are common: bacterial vaginosis, candidal vaginitis, trichomonas vaginitis, senile vaginitis, and juvenile vaginitis.
Bacterial Vaginitis (BV) is a syndrome of increased vaginal secretion caused by mixed infection of gardnerella vaginalis and anaerobic bacteria, which results in imbalance of microecological balance in vagina, and white with fishy smell and pruritus vulvae. Bacterial vaginitis is classified into haemophilus vaginitis, corynebacterium vaginitis, anaerobic vaginitis, gardnerella vaginitis, etc.
Currently, attempts are made to treat the affected area with oral or direct administration of antibiotics, antifungals or combinations, depending on the cause of the infection. In infectious vaginitis, gardnerella vaginalis and candida albicans are main microorganisms causing vaginitis, and after the pathogenic bacteria are infected, excessive antibiotics, stress, primary vaginitis caused by intrinsic factors and the like are caused, the amount of lactobacillus capable of generating hydrogen peroxide in the vagina is reduced, the direct sterilization effect of the hydrogen peroxide is reduced, and the lactic acid production amount is reduced, so that the pH value is increased, and various bacteria are easy to grow. Therefore, providing a lactic acid bacterium that inhibits the growth of pathogenic bacteria and that has a high hydrogen peroxide yield can play an important role in improving female reproductive health.
Disclosure of Invention
The application aims to provide lactobacillus reuteri capable of improving colpitis and application thereof, wherein the lactobacillus reuteri has a certain antibacterial effect on gardnerella vaginalis, staphylococcus aureus and candida albicans, and meanwhile, hydrogen peroxide can be produced at high yield, so that the lactobacillus reuteri can improve colpitis caused by microbial infection.
In order to achieve the above object of the present application, the following technical solutions are specifically adopted:
in a first aspect the present application provides a lactobacillus reuteri, in particular lactobacillus reuteri (Limosilactobacillus reuteri) HR7, deposited with the cantonese collection of microbial strains under accession number GDMCC No:63350, the preservation time is 2023, 04 and 14.
In a second aspect, the application provides a microbial preparation comprising said lactobacillus reuteri.
In a third aspect the application provides a metagen of the above lactobacillus reuteri.
In a fourth aspect, the present application provides the use of at least one of said lactobacillus reuteri, said microbial agent and said metazoan for the manufacture of a vaginal care product.
The fourth aspect of the application provides an application of at least one of lactobacillus reuteri, the microbial preparation and the metazoan in preparing medicines or foods for preventing and treating colpitis.
Preferably, the vaginitis is vaginitis caused by at least one of candida albicans, staphylococcus aureus and gardnerella vaginalis.
Preferably, the pharmaceutical dosage forms include lotions, gels and ointments.
In a fifth aspect, the present application provides a medicament for preventing and treating vaginitis, the medicament comprising at least one of the lactobacillus reuteri, the microbial preparation and the metazoan, and pharmaceutically acceptable auxiliary materials.
Preferably, the pharmaceutical dosage forms include lotions, gels and ointments.
Preferably, the content of lactobacillus reuteri in the medicament is 10 6 ～10 10 cfu/ml, the content of metazoan is 10-100 mg/g.
Compared with the prior art, the application has the beneficial effects that at least:
the lactobacillus reuteri has certain antibacterial effect on gardnerella vaginalis, staphylococcus aureus and candida albicans, and can produce hydrogen peroxide at high yield, so that the lactobacillus reuteri can improve colpitis caused by microbial infection; therefore, the lactobacillus reuteri can be used for preparing vaginal care products and medicines for preventing and treating vaginitis, can establish a vaginal microecological barrier and delay genital tract aging, and provides powerful guarantee for female reproductive health.
Detailed Description
Embodiments of the technical scheme of the present application will be described in detail below with reference to the embodiments. The following examples are only for more clearly illustrating the technical aspects of the present application, and thus are merely examples, and are not intended to limit the scope of the present application.
It is noted that unless otherwise indicated, technical or scientific terms used herein should be given the ordinary meaning as understood by one of ordinary skill in the art to which this application belongs.
The embodiment of the application provides lactobacillus reuteri for improving colpitis, in particular lactobacillus reuteri (Limosilactobacillus reuteri) HR7, which is preserved in the Guangdong province microorganism strain preservation center, and the preservation number is GDMCC No:63350, the preservation time is 2023, 04 and 14.
In yet another embodiment of the present application, a microbial preparation containing the lactobacillus reuteri is provided.
In another embodiment of the present application, a metagen of the above lactobacillus reuteri is provided.
The lactobacillus reuteri has certain antibacterial effect on gardnerella vaginalis, staphylococcus aureus and candida albicans, and can produce hydrogen peroxide at high yield, so that the lactobacillus reuteri can improve colpitis caused by microbial infection.
In a further embodiment, the application provides an application of at least one of lactobacillus reuteri, the microbial preparation and the metazoan in preparing a vaginal care product.
The application further provides an application of at least one of lactobacillus reuteri, the microbial preparation and the metazoan in preparing medicines or foods for preventing and treating colpitis.
Further, the vaginitis is vaginitis caused by at least one of candida albicans, staphylococcus aureus and gardnerella vaginalis.
The dosage form of the above-mentioned medicament is not strictly limited by the present application, and those skilled in the art can use conventional dosage forms in the art, for example, in one embodiment, the medicament dosage form is a lotion, in another embodiment, the medicament dosage form is a gel, and in other embodiments, the medicament dosage form is an ointment.
In another embodiment, the application provides a medicament for preventing and treating colpitis, which comprises at least one of lactobacillus reuteri, the microbial preparation and the metazoan, and pharmaceutically acceptable auxiliary materials.
Further, pharmaceutical dosage forms include lotions, gels and ointments.
In order to better improve the effect of the drug on preventing and treating colpitis, in one embodiment, the content of the lactobacillus reuteri in the drug is 10 6 ～10 10 cfu/ml, the content of metazoan is 10-100 mg/g.
In order to better explain the technical scheme of the application, the technical scheme of the application is further described in detail through specific embodiments.
Example 1
This example shows a screening procedure for lactobacillus reuteri HR 7:
collecting a plurality of parts of Jiangsu Rugao healthy female vagina samples by using a disposable sterile sampler, carrying out gradient dilution, then coating on an MRS culture medium, and carrying out enrichment culture in an anaerobic incubator for 48 hours; after culturing, according to the color, size, edge shape and the like of the bacterial colony, picking the bacterial colony to score pure by an inoculating loop; the obtained colony is subjected to gram staining and catalase analysis, gram staining positive bacteria and catalase negative bacteria are reserved, and the strain with the best effect is selected to obtain the strain HR7.
Example 2
The present example is the identification of the strains screened as described above;
classifying and identifying the bacterial strain HR7 by adopting a 16S rDNA gene sequencing method, and culturing and observing morphological characteristics of the bacterial strain HR 7;
the genome of lactobacillus reuteri HR7 was extracted, and 16S rDNA series amplification and sequencing was performed, with the following sequencing results: AGGCTCAGGATGAACGCCGGCGGTGTGCCTAATACATGCAAGTCGTACGCACTGGCCCAACTGATTGATGGTGCTTGCACCTGATTGACGATGGATCACCAGTGAGTGGCGGACGGGTGAGTAACACGTAGGTAACCTGCCCCGGAGCGGGGGATAACATTTGGAAACAGATGCTAATACCGCATAACAACAAAAGCCACATGGCTTTTGTTTGAAAGATGGCTTTGGCTATCACTCTGGGATGGACCTGCGGTGCATTAGCTAGTTGGTAAGGTAACGGCTTACCAAGGCGATGATGCATAGCCGAGTTGAGAGACTGATCGGCCACAATGGAACTGAGACACGGTCCATACTCCTACGGGAGGCAGCAGTAGGGAATCTTCCACAATGGGCGCAAGCCTGATGGAGCAACACCGCGTGAGTGAAGAAGGGTTTCGGCTCGTAAAGCTCTGTTGTTGGAGAAGAACGTGCGTGAGAGTAACTGTTCACGCAGTGACGGTATCCAACCAGAAAGTCACGGCTAACTACGTGCCAGCAGCCGCGGTAATACGTAGGTGGCAAGCGTTATCCGGATTTATTGGGCGTAAAGCGAGCGCAGGCGGTTGCTTAGGTCTGATGTGAAAGCCTTCGGCTTAACCGAAGAAGTGCATCGGAAACCGGGCAACTTGAGTGCAGAAGAGGACAGTGGAACTCCATGTGTAGCGGTGGAATGCGTAGATATATGGAAGAACACCAGTGGCGAAGGCGGCTGTCTGGTCTGCAACTGACGCTGAGGCTCGAAAGCATGGGTAGCGAACAGGATTAGATACCCTGGTAGTCCATGCCGTAAACGATGAGTGCTAGGTGTTGGAGGGTTTCCGCCCTTCAGTGCCGGAGCTAACGCATTAAGCACTCCGCCTGGGGAGTACGACCGCAAGGTTGAAACTCAAAGGAATTGACGGGGGCCCGCACAAGCGGTGGAGCATGTGGTTTAATTCGAAGCTACGCGAAGAACCTTACCAGGTCTTGACATCTTGCGCTAACCTTAGAGATAAGGCGTTCCCTTCGGGGACGCAATGACAGGTGGTGCATGGTCGTCGTCAGCTCGTGTCGTGAGATGTTGGGTTAAGTCCCGCAACGAGCGCAACCCTTGTTACTAGTTGCCAGCATTAAGTTGGGCACTCTAGTGAGACTGCCGGTGACAAACCGGAGGAAGGTGGGGACGACGTCAGATCATCATGCCCCTTATGACCTGGGCTACACACGTGCTACAATGGACGGTACAACGAGTCGCAAGCTCGCGAGAGTAAGCTAATCTCTTAAAGCCGTTCTCAGTTCGGACTGTAGGCTGCAACTCGCCTACACGAAGTCGGAATCGCTAGTAATCGCGGATCAGCATGCCGCGGTGAATACGTTCCCGGGCCTTGTACACACCGCCCGTCACACCATGGGAGTTTGTAACGCCCAAAGTCGGTGGCCTAACCTTTATGGAGGGAGCCGCCTAAGGCGGGACAGATGACTGGGGTGAAGTCGTAA;
morphological characterization of strain HR7 was characterized as follows: the bacillus-free bacteria which are gram-positive are streaked on MRS culture medium to form obvious bacterial colony after 48 hours of culture, the diameter is between 0.2 and 2.5mm, and the bacillus-free bacteria are round, slightly white, convex and opaque.
The screened strain HR7 is determined to be lactobacillus reuteri HR7 through the alignment of the 16S rRNA and morphological characteristics.
Example 3
This example shows the inhibition of the above-mentioned Lactobacillus reuteri HR7 against Gardnerella vaginalis (KCTC 5096), candida albicans (KCTC 7678) and Staphylococcus aureus (ATCC 25923):
activating lactobacillus reuteri HR7, inoculating into MRS liquid culture medium, and culturing to obtain 1×10 concentration 8 cfu/ml of culture solution;
activating Gardnerella vaginalis, candida albicans and Staphylococcus aureus respectively, inoculating into MRS culture medium, and culturing to obtain 1×10 concentration 8 cfu/ml of culture solution;
will be 1X 10 8 3 parts of cfu/ml of lactobacillus reuteri HR7 culture solution are taken, and each part is 3ml;
the concentration is 1 multiplied by 10 8 2 parts of culture solution of gardnerella vaginalis, candida albicans and staphylococcus aureus are respectively taken from cfu/ml, wherein 1 part of culture solution is 3ml in volume, and the other part of culture solution is 6ml;
mixing 3 parts of lactobacillus reuteri HR7 culture solution with 3ml of gardnerella vaginalis, candida albicans and staphylococcus aureus culture solution respectively, and sequentially marking as an experiment 1 group, an experiment 2 group and an experiment 3 group respectively, wherein the rest 3 parts of gardnerella vaginalis, candida albicans and staphylococcus aureus culture solution sequentially serve as a control group, and sequentially marking as a control 1 group, a control 2 group and a control 3 group;
respectively inoculating the experiment 1 group, the experiment 2 group, the experiment 3 group, the control 1 group, the control 2 group and the control 3 group into MRS liquid culture medium for culturing for 20 hours to obtain culture solutions respectively;
100. Mu.l of each of the above-mentioned different media was inoculated into 20ml of a selective medium of Gardnerella vaginalis, candida albicans and Staphylococcus aureus, and then, gardnerella vaginalis, candida albicans and Staphylococcus aureus were counted, and the counting results are shown in Table 1;
TABLE 1
As shown in Table 1, the Lactobacillus reuteri HR7 of the present application has excellent inhibitory effect on Gardnerella vaginalis, candida albicans and Staphylococcus aureus.
Example 4
The experimental study of the hydrogen peroxide production performance of lactobacillus reuteri HR7 is shown in the example:
the mass fraction of H was 30% using 100mmol/L piperazine-N, N' -di-ethane sulfonic acid (PIPES) 2 O 2 Diluted to 1mol/L and 1mol/L H with 100mmol/L PIPES 2 O 2 Diluting into 0 mu mol/L, 20 mu mol/L, 40 mu mol/L, 60 mu mol/L, 80 mu mol/L and 100 mu mol/L solutions respectively; then 100. Mu.L of the above H was taken separately 2 O 2 Mixing the solution with 100 mu L of 20mmol/L TMB, adding 2 mu L of horseradish peroxidase (1 mg/mL) into the mixed solution, uniformly mixing, incubating at 16 ℃ for 10min, measuring OD600 and drawing a standard curve;
activating the lactobacillus reuteri HR7 of the application, inoculating the activated lactobacillus reuteri HR7 into MRS culture medium for culturing overnight, wherein the inoculating concentration is 10 8 cfu/ml, and centrifuging to obtain supernatant;
mu.L of the supernatant was aspirated and mixed with 100. Mu.L of 20mmol/L TMB, and finally 2. Mu.L of horseradish peroxidase (1 mg/mL) was added to the mixed solution and mixed well, incubated at 16℃for 10min, OD600 was measured, and the concentration of hydrogen peroxide in the supernatant was calculated according to a standard curve.
The calculation result is H 2 O 2 The concentration is 28.62 mu mol/L, and the lactobacillus reuteri HR7 has a certain hydrogen peroxide production capacity.
In conclusion, the lactobacillus reuteri has certain antibacterial effect on gardnerella vaginalis, staphylococcus aureus and candida albicans, and can produce hydrogen peroxide at high yield, so that the lactobacillus reuteri can improve colpitis caused by microbial infection; therefore, the lactobacillus reuteri can be used for preparing vaginal care products and medicines for preventing and treating vaginitis, and provides powerful guarantee for female reproductive health.
Finally, it should be noted that: the above embodiments are only for illustrating the technical solution of the present application, and not for limiting the same; although the application has been described in detail with reference to the foregoing embodiments, it will be understood by those of ordinary skill in the art that: the technical scheme described in the foregoing embodiments can be modified or some or all of the technical features thereof can be replaced by equivalents; such modifications and substitutions do not depart from the spirit of the application, and are intended to be included within the scope of the appended claims and description.
Claims (10)
1. Lactobacillus reuteri with improved colpitis, characterized in that it is in particular lactobacillus reuteri (Limosilactobacillus reuteri) HR7, deposited with the collection of microorganism strains in the cantonese province under the accession number GDMCC No:63350.
2. a microbial preparation comprising lactobacillus reuteri according to claim 1.
3. The metagen of lactobacillus reuteri of claim 1.
4. Use of at least one of lactobacillus reuteri according to claim 1, a microbial preparation according to claim 2 and a metazoan according to claim 3 for the manufacture of a vaginal care product.
5. Use of at least one of lactobacillus reuteri according to claim 1 and/or a microbial preparation according to claim 2 and a metazoan according to claim 3 for the manufacture of a medicament or food for the prevention and treatment of vaginitis.
6. The use according to claim 5, wherein the vaginitis is vaginitis caused by at least one of candida albicans, staphylococcus aureus and gardnerella vaginalis.
7. The use according to claim 5, wherein the pharmaceutical dosage forms comprise lotions, gels and ointments.
8. A medicament for preventing and treating vaginitis, which comprises at least one of lactobacillus reuteri according to claim 1, a microbial preparation according to claim 2 and a metazoan according to claim 3, and pharmaceutically acceptable auxiliary materials.
9. The medicament of claim 8, wherein the pharmaceutical dosage form comprises a lotion, a gel, and an ointment.
10. The medicament according to claim 8, wherein the content of lactobacillus reuteri in the medicament is 10 6 ～10 10 cfu/ml, the content of metazoan is 10-100 mg/g.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202310556089.9A CN116751705B (en) | 2023-05-17 | 2023-05-17 | Lactobacillus reuteri with effect of improving colpitis and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202310556089.9A CN116751705B (en) | 2023-05-17 | 2023-05-17 | Lactobacillus reuteri with effect of improving colpitis and application thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN116751705A true CN116751705A (en) | 2023-09-15 |
| CN116751705B CN116751705B (en) | 2024-03-15 |
Family
ID=87952252
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202310556089.9A Active CN116751705B (en) | 2023-05-17 | 2023-05-17 | Lactobacillus reuteri with effect of improving colpitis and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN116751705B (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN117511826A (en) * | 2024-01-02 | 2024-02-06 | 四川厌氧生物科技有限责任公司 | Lactobacillus mucilaginosus and application thereof |
Citations (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW201136597A (en) * | 2010-04-30 | 2011-11-01 | Glac Biotech Co Ltd | Anti-inflammatory and anti-vaginitis food composition and pharmaceutical composition containing Lactobacillus |
| CN107267415A (en) * | 2017-06-23 | 2017-10-20 | 广东龙创基药业有限公司 | A kind of lactobacillus reuteri and its application for preparing vagina antibacterial medicines |
| CN110373342A (en) * | 2018-04-13 | 2019-10-25 | 深圳市华大农业应用研究院 | Lactobacillus reuteri and application thereof |
| WO2021070093A1 (en) * | 2019-10-10 | 2021-04-15 | Buzzelet Development And Technologies Ltd. | Cannabidiol-enhanced probiotic compositions and uses thereof for treatment of infections |
| CN114350560A (en) * | 2022-01-05 | 2022-04-15 | 江南大学 | Lactobacillus paracasei for inhibiting growth and biomembrane of gardnerella vaginalis and producing hydrogen peroxide at high yield |
| WO2022100633A1 (en) * | 2020-11-10 | 2022-05-19 | 深圳华大生命科学研究院 | Lactobacillus gasseri for prevention and/or treatment of reproductive tract flora disorder-related diseases |
| US20220193157A1 (en) * | 2020-12-23 | 2022-06-23 | Church & Dwight Co., Inc. | Lactobacillus compositions and methods for prevention and treatment of microbial infection |
| CN114990011A (en) * | 2022-05-25 | 2022-09-02 | 江西仁仁健康产业有限公司 | Lactobacillus reuteri capable of reducing cholesterol and inhibiting gardnerella and application |
-
2023
- 2023-05-17 CN CN202310556089.9A patent/CN116751705B/en active Active
Patent Citations (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW201136597A (en) * | 2010-04-30 | 2011-11-01 | Glac Biotech Co Ltd | Anti-inflammatory and anti-vaginitis food composition and pharmaceutical composition containing Lactobacillus |
| CN107267415A (en) * | 2017-06-23 | 2017-10-20 | 广东龙创基药业有限公司 | A kind of lactobacillus reuteri and its application for preparing vagina antibacterial medicines |
| CN110373342A (en) * | 2018-04-13 | 2019-10-25 | 深圳市华大农业应用研究院 | Lactobacillus reuteri and application thereof |
| WO2021070093A1 (en) * | 2019-10-10 | 2021-04-15 | Buzzelet Development And Technologies Ltd. | Cannabidiol-enhanced probiotic compositions and uses thereof for treatment of infections |
| WO2022100633A1 (en) * | 2020-11-10 | 2022-05-19 | 深圳华大生命科学研究院 | Lactobacillus gasseri for prevention and/or treatment of reproductive tract flora disorder-related diseases |
| US20220193157A1 (en) * | 2020-12-23 | 2022-06-23 | Church & Dwight Co., Inc. | Lactobacillus compositions and methods for prevention and treatment of microbial infection |
| CN114350560A (en) * | 2022-01-05 | 2022-04-15 | 江南大学 | Lactobacillus paracasei for inhibiting growth and biomembrane of gardnerella vaginalis and producing hydrogen peroxide at high yield |
| CN114990011A (en) * | 2022-05-25 | 2022-09-02 | 江西仁仁健康产业有限公司 | Lactobacillus reuteri capable of reducing cholesterol and inhibiting gardnerella and application |
Non-Patent Citations (2)
| Title |
|---|
| 杜志琳;尹望;李雪平;: "一株罗伊氏乳杆菌的分离鉴定及其益生性能研究", 饲料研究, no. 11 * |
| 钟燕;INGE TARNOW;隋龙;: "鼠李糖乳杆菌GR-1和罗伊氏乳杆菌RC-14防治阴道炎的研究进展", 国际妇产科学杂志, no. 05 * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN117511826A (en) * | 2024-01-02 | 2024-02-06 | 四川厌氧生物科技有限责任公司 | Lactobacillus mucilaginosus and application thereof |
| CN117511826B (en) * | 2024-01-02 | 2024-03-15 | 四川厌氧生物科技有限责任公司 | Lactobacillus mucilaginosus and application thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN116751705B (en) | 2024-03-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN110656060B (en) | Multi-linked lactobacillus composition and application thereof in female vaginal health | |
| CN107299065B (en) | Lactobacillus plantarum and application thereof in preparation of vagina bacteriostatic drugs | |
| CN108004187A (en) | A kind of lactobacillus gasseri and its application for being used to prepare vagina antibacterial medicines | |
| TW201531560A (en) | Lactobacillus crispatus and application thereof | |
| CN108004188B (en) | Lactobacillus rhamnosus and application thereof in preparing vagina bacteriostatic medicine | |
| CN113862188B (en) | Lactobacillus gasseri LS03 and application thereof | |
| CN116751705B (en) | Lactobacillus reuteri with effect of improving colpitis and application thereof | |
| CN114561330B (en) | Composite microbial inoculum for preventing and treating genital tract infection | |
| CN114642686B (en) | Composite probiotics and its functions of delaying senility and resisting oxidation | |
| CN103409334A (en) | Lactobacillus for inhibiting pathogenic bacteria of vaginitis and application thereof | |
| CN115851504B (en) | Probiotics, compositions and uses thereof | |
| CN117143767B (en) | Breast milk-derived fermented lactobacillus mucilaginosus MSJK capable of regulating intestinal flora and application thereof | |
| CN114836349B (en) | Lactobacillus acidophilus LA16 for antagonizing helicobacter pylori and application thereof | |
| CN117535208B (en) | Lactobacillus crispatus and application thereof in female genital tract health | |
| CN110540945A (en) | lactobacillus jensenii and application thereof in preparation of vaginal antibacterial drugs | |
| CN113512516B (en) | Cooperative swine-origin lactobacillus mucosae and application thereof | |
| CN117683691A (en) | Lactobacillus reuteri and application thereof in preparation of medicines for preventing and treating vaginitis | |
| CN104293718B (en) | Lactobacillus jensenii and application thereof | |
| CN115261251B (en) | Streptococcus thermophilus S869 and application thereof in regulating immunity and intestinal functions | |
| CN114480198A (en) | Lactobacillus crispatus strain for vagina and application thereof | |
| CN113508907A (en) | Application of heat-resistant lactobacillus fermentum in preparation of defecation promoting food or medicine | |
| CN117511826B (en) | Lactobacillus mucilaginosus and application thereof | |
| CN117535209B (en) | Lactobacillus brevis and application thereof in female genital tract health | |
| CN115386523B (en) | Lactococcus lactis and application thereof in resisting helicobacter pylori infection | |
| CN117535206B (en) | Lactobacillus salivarius and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |